BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 34807269)

  • 41. Value of threshold growth as a major diagnostic feature of hepatocellular carcinoma in LI-RADS.
    Choi SJ; Choi SH; Kim DW; Kwag M; Byun JH; Won HJ; Shin YM
    J Hepatol; 2023 Mar; 78(3):596-603. PubMed ID: 36402451
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diagnostic Performance of LI-RADS v2018 versus KLCA-NCC 2018 Criteria for Hepatocellular Carcinoma Using Magnetic Resonance Imaging with Hepatobiliary Agent: A Systematic Review and Meta-Analysis of Comparative Studies.
    Shin J; Lee S; Yoon JK; Son WJ; Roh YH; Chung YE; Choi JY; Park MS
    Gut Liver; 2023 May; 17(3):466-474. PubMed ID: 36317516
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Liver Imaging Reporting and Data System version 2018 category 5 for diagnosing hepatocellular carcinoma: an updated meta-analysis.
    Lee S; Kim YY; Shin J; Roh YH; Choi JY; Chernyak V; Sirlin CB
    Eur Radiol; 2024 Mar; 34(3):1502-1514. PubMed ID: 37656177
    [TBL] [Abstract][Full Text] [Related]  

  • 44. LI-RADS for CT diagnosis of hepatocellular carcinoma: performance of major and ancillary features.
    Alhasan A; Cerny M; Olivié D; Billiard JS; Bergeron C; Brown K; Bodson-Clermont P; Castel H; Turcotte S; Perreault P; Tang A
    Abdom Radiol (NY); 2019 Feb; 44(2):517-528. PubMed ID: 30167771
    [TBL] [Abstract][Full Text] [Related]  

  • 45. LI-RADS major features: CT, MRI with extracellular agents, and MRI with hepatobiliary agents.
    Santillan C; Fowler K; Kono Y; Chernyak V
    Abdom Radiol (NY); 2018 Jan; 43(1):75-81. PubMed ID: 28828680
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Can contrast enhanced ultrasound differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma?
    Huang JY; Li JW; Ling WW; Li T; Luo Y; Liu JB; Lu Q
    World J Gastroenterol; 2020 Jul; 26(27):3938-3951. PubMed ID: 32774068
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identification of the origin of tumor in vein: comparison between CEUS LI-RADS v2017 and v2016 for patients at high risk.
    Tong WJ; Cheng MQ; Lin MX; Hu HT; Pan JM; Huang H; Wang Y; Xie XY; Lu MD; Kuang M; Huang Y; Wang W
    BMC Med Imaging; 2022 Oct; 22(1):186. PubMed ID: 36309665
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Should Threshold Growth Be Considered a Major Feature in the Diagnosis of Hepatocellular Carcinoma Using LI-RADS?
    Park JH; Chung YE; Seo N; Choi JY; Park MS; Kim MJ
    Korean J Radiol; 2021 Oct; 22(10):1628-1639. PubMed ID: 34269533
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inter-reader reliability of CT Liver Imaging Reporting and Data System according to imaging analysis methodology: a systematic review and meta-analysis.
    Kang JH; Choi SH; Lee JS; Kim KW; Kim SY; Lee SS; Byun JH
    Eur Radiol; 2021 Sep; 31(9):6856-6867. PubMed ID: 33713172
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tumor in vein (LR-TIV) and liver imaging reporting and data system (LI-RADS) v2018: diagnostic features, pitfalls, prognostic and management implications.
    Catania R; Chupetlovska K; Borhani AA; Maheshwari E; Furlan A
    Abdom Radiol (NY); 2021 Dec; 46(12):5723-5734. PubMed ID: 34519877
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Liver Imaging Reporting and Data System (LI-RADS) v2018: diagnostic value of ancillary features favoring malignancy in hypervascular observations ≥ 10 mm at intermediate (LR-3) and high probability (LR-4) for hepatocellular carcinoma.
    Cannella R; Vernuccio F; Sagreiya H; Choudhury KR; Iranpour N; Marin D; Furlan A
    Eur Radiol; 2020 Jul; 30(7):3770-3781. PubMed ID: 32107603
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Threshold growth has a limited role in differentiating hepatocellular carcinoma from other focal hepatic lesions.
    Lyu R; Wang D; Hu W; Gao Z; Yu C; Wang J; Li M; Jia K
    BMC Med Imaging; 2023 Dec; 23(1):201. PubMed ID: 38049717
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An improved diagnostic algorithm for subcentimeter hepatocellular carcinoma on gadoxetic acid-enhanced MRI.
    Huang P; Zhou C; Wu F; Xiao Y; Qian X; Wang Y; Yang C; Zeng M
    Eur Radiol; 2023 Apr; 33(4):2735-2745. PubMed ID: 36472696
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Liver Imaging Reporting and Data System categories: Long-term imaging outcomes in a prospective surveillance cohort.
    Kim BJ; Choi SH; Kim SY; Lim YS; Lee SJ; Byun JH; Won HJ
    Liver Int; 2022 Jul; 42(7):1648-1657. PubMed ID: 35445513
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Diagnosis of Non-Hepatocellular Carcinoma Malignancies in Patients With Risks for Hepatocellular Carcinoma: CEUS LI-RADS Versus CT/MRI LI-RADS.
    Hu YX; Shen JX; Han J; Mao SY; Mao RS; Li Q; Li F; Guo ZX; Zhou JH
    Front Oncol; 2021; 11():641195. PubMed ID: 33912456
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Diagnostic Performance of LI-RADS Version 2018 for Evaluation of Pediatric Hepatocellular Carcinoma.
    Khanna G; Chavhan GB; Schooler GR; Fraum TJ; Alazraki AL; Squires JH; Salter A; Podberesky DJ; Towbin AJ
    Radiology; 2021 Apr; 299(1):190-199. PubMed ID: 33620289
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inter-reader reliability of contrast-enhanced ultrasound Liver Imaging Reporting and Data System: a meta-analysis.
    Kang JH; Choi SH; Lee JS; Kim DW; Jang JK
    Abdom Radiol (NY); 2021 Oct; 46(10):4671-4681. PubMed ID: 34156509
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Data-Driven Modification of the LI-RADS Major Feature System on Gadoxetate Disodium-Enhanced MRI: Toward Better Sensitivity and Simplicity.
    Jiang H; Song B; Qin Y; Wei Y; Konanur M; Wu Y; Zaki IH; McInnes MDF; Lafata KJ; Bashir MR
    J Magn Reson Imaging; 2022 Feb; 55(2):493-506. PubMed ID: 34236120
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hepatocellular carcinoma (HCC) versus non-HCC: accuracy and reliability of Liver Imaging Reporting and Data System v2018.
    Ludwig DR; Fraum TJ; Cannella R; Ballard DH; Tsai R; Naeem M; LeBlanc M; Salter A; Tsung A; Shetty AS; Borhani AA; Furlan A; Fowler KJ
    Abdom Radiol (NY); 2019 Jun; 44(6):2116-2132. PubMed ID: 30798397
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Differentiation of hepatocellular carcinoma from intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in high-risk patients matched to MR field strength: diagnostic performance of LI-RADS version 2018.
    Zou X; Luo Y; Morelli JN; Hu X; Shen Y; Hu D
    Abdom Radiol (NY); 2021 Jul; 46(7):3168-3178. PubMed ID: 33660040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.